Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the ...

These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...

Bayer expects its pharmaceutical business to return to growth in 2027 as the launch new therapies is expected to offset ...

A Washington jury on Tuesday ordered Bayer to pay $100 million to four people who say they were sickened by toxic chemicals ...

Bayer’s deal with Genpact opens up new ground for pharma’s use of artificial intelligence ... as with last month’s collaboration between Orbita and a US hospital. The FDA has placed the ...

Despite restructuring efforts, Bayer's financial outlook for 2025 remains ... Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.

It will also take ownership of a contract business in the US, where Endo Pharmaceuticals licenses Nebido from Bayer and sells it under the Aveed brand name. The two companies said the transaction ...

Look no further than our top two stories of the year and you’ll see that the GLP-1 craze and Big Pharma layoffs took ... and Fierce’s January coverage of Bayer’s restructuring rounded ...

Bayer BAYN1.13%increase ... a win for the German pharmaceutical and agricultural conglomerate that still faces litigation in the U.S. The group has been hounded by lawsuits since 2018 when ...